Novo Nordisk Launches New Trial for Low-Dose Oral Wegovy Tablets
Nashnova编辑部
Novo Nordisk has launched a new clinical trial testing whether oral Wegovy can maintain weight loss at lower doses — if it works, patient costs could drop to roughly half the current high-dose price.
What exactly is this trial testing?
One core question: how low can the oral Wegovy dose go while still keeping weight off?
The trial enrolled 450 patients, comparing two undisclosed low-dose regimens against placebo. Entry threshold is a BMI ≥ 27 — the WHO definition of overweight.
This means → Novo Nordisk is not developing a new drug. It is looking for a cheaper way to take one that already works.
How is oral Wegovy selling so far?
Since its U.S. launch in January, prescriptions have topped 5 million, rapidly claiming share in a crowded obesity-drug market.
In plain terms = a single oral weight-loss pill racking up 5 million scripts in barely seven months signals enormous demand.
What would a lower dose mean for patients?
In the U.S. market today, the two lower-dose versions cost roughly half the out-of-pocket price of the two higher-dose versions.
This means → if the trial confirms that lower doses work, the financial barrier drops significantly, opening the drug to a wider pool of overweight patients.
This reflects Novo Nordisk's playbook — crack the market with higher doses, then broaden the base with cheaper ones.
Content is for reference only, not financial advice.